The biggest trade is efficacy versus daily attention. An IUD or implant means one clinic visit, then nothing to remember for years, with under 0.2% failure. A pill means daily attention and a 9% real-world failure rate — almost all of that gap is forgotten doses. The non-contraceptive perks are real: lighter periods, less pain, clearer skin, lower ovarian cancer risk for decades after you stop. The mood signal is real too, especially in the first months and especially for teens — if you feel worse, switch.
The hormones do three things. Estrogen suppresses the brain signal that triggers ovulation. Progestin blocks the ovulation surge directly and thickens cervical mucus into a sperm barrier. Combined methods — most pills, the patch, the ring — use both. Progestin-only methods — the implant, the injection, the hormonal IUD, the mini-pill — skip estrogen, which is what makes them safer for clot-prone or breastfeeding users.
Where the hormone is delivered changes how much enters the bloodstream. Pills, patches, rings, and injections circulate it everywhere. The hormonal IUD releases progestin into the uterus, with only a small fraction reaching the blood — which is why people with heavy periods can see dramatic relief without much systemic effect CDC US-MEC 2016.
What the numbers actually look like
Method choice dominates everything else. The Contraceptive CHOICE Project — 7,486 women, three years, every method free — pinned the typical-use failure rates that matter, and the gap between methods you have to remember and methods you don't turned out to be enormous.
The long-term cohort data is more encouraging than the public conversation suggests. Ever-users of combined pills have lower lifetime risk of ovarian, endometrial, and colorectal cancers, no overall cancer-incidence increase, and modestly lower all-cause mortality — the 44-year Royal College follow-up of 46,022 women Iversen et al. 2017 Hannaford et al. 2010. Ovarian cancer protection alone runs about 20% lower risk per five years of use, and the protection holds three decades after stopping Collaborative Group 2008.
The risks are real but small in absolute terms and method-dependent. Combined methods raise clot risk, sharply for some progestin types and modestly for others.
Combined pills also raise stroke and heart attack risk. The absolute numbers stay small for a young healthy woman and multiply sharply if you smoke and are over 35 Lidegaard et al. 2012. The breast cancer signal is small and time-limited: about one extra case per 7,690 women per year of current use, fading within a decade of stopping Mørch et al. 2017. The cervical cancer signal also fades within a decade of stopping IARC 2007. Progestin-only methods carry essentially none of the clot, stroke, or estrogen-related risks CDC US-MEC 2016.
Picking a method
The decision is mostly about three trade-offs: efficacy versus daily attention, estrogen versus no estrogen, and how you want your periods to look.
Most clinicians will hand you a version of this flowchart. If yours doesn't, ask. The default first-line in current US and WHO guidance is an IUD or implant, mostly because typical-use efficacy is so much better than for short-acting methods CDC US-MEC 2016.
When the combined methods are off the table
The combined methods — pill, patch, ring — have a real don't-do-this list, built around clot and stroke risk. Progestin-only methods (IUD, implant, injection, mini-pill) clear nearly all of it WHO MEC 2015.
Where it lands differently
Teenagers carry the largest mood signal in the data. The Danish national cohort found roughly 80% higher rates of starting an antidepressant in 15-to-19-year-olds within the first six months of any hormonal method, versus about 23% in adult users Skovlund et al. 2016. That doesn't mean don't prescribe — most teens do fine — it means watch the first months closely and switch fast if mood drops.
Postpartum, the combined methods are off the table for at least three weeks because clot risk peaks right after birth — longer if you're breastfeeding. Progestin-only methods, the hormonal IUD, and the copper IUD are all compatible with nursing CDC US-MEC 2016.
In the run-up to menopause, hormonal contraception does double duty: pregnancy is still possible, and the same hormones tame heavy bleeding, hot flashes, and irregular cycles. The hormonal IUD pairs well with this transition, including as the progestin half of menopausal hormone therapy later on.
If you want no hormones
The copper IUD is the closest non-hormonal equivalent: under 1% failure per year, ten-plus years per device, no systemic effects. The trade is heavier and crampier periods, especially for the first six months Trussell 2011.
Condoms are the only contraceptive that also blocks STIs, but typical-use failure runs around 18% per year — high enough that condoms-only is rarely the long-term plan for users who don't want pregnancy.
Fertility-awareness methods vary widely. Well-taught users of the symptothermal method get to 2-5% typical-use failure; users of phone apps as commonly used get closer to 15-25%. They work for engaged users with stable cycles.
Tubal ligation and vasectomy end the question permanently. Vasectomy is the simpler procedure with shorter recovery; tubal ligation is more invasive but available when a partner won't or can't have one.
What people get wrong
The pill doesn't make you gain weight. Controlled comparisons consistently find no clinically meaningful difference between combined pills and placebo. The single exception is the injection (DMPA), which adds about 2-3 kg in the first year for many users.
The pill doesn't ruin your fertility. Ovulation resumes within a couple of cycles for nearly everyone stopping pills, patch, ring, IUD, or implant. The injection is the outlier — return to ovulation can take 6 to 12 months, occasionally longer Kaunitz et al. 2008.
The injection's bone effect mostly reverses. DMPA reduces bone density during use — about 5-7% over two years, which earned an FDA warning — but density recovers toward baseline after stopping Kaunitz et al. 2008. For adolescents whose bones are still accruing, this is a real consideration and a reason to think twice about multi-year DMPA use. For adults on it for a year or two, it usually isn't.
You don't need to take a break. Cycling on and off doesn't reset anything biologically; it just raises your chance of an unintended pregnancy during the gap.
How it actually goes wrong
The pill goes wrong by being forgotten. Missing one dose is usually fine; missing two raises ovulation risk fast. The patch goes wrong by peeling off in a sweaty week. The ring goes wrong by being out of place more than three hours. The injection goes wrong by drifting past the 13-week mark. And it can fail chemically — St John's wort, and a handful of prescription drugs that rev up the same liver enzymes, clear the hormones faster and quietly drop a combined pill below the line of protection, so run any new supplement or medication past your method first.
The other way it goes wrong is by waiting too long on a method that isn't working. If mood drops noticeably in the first three months on any hormonal method, the right move is to switch — to a different progestin, a non-hormonal method, or off entirely — not to ride it out. The mood signal in the literature is concentrated in those early months Skovlund et al. 2018. If libido drops and stays down, same answer: switch, don't tough it out. The advice to "give it three months" applies to bleeding patterns, not to mood or desire Pastor et al. 2013.
What this looks like in real life
In the US under the ACA, all FDA-approved methods are covered with no copay on most insurance plans. Without insurance: generic pills run $15-50 a month; the patch and ring run more; the injection runs $30-150 every three months. IUDs and implants run $0 to about $1,300 up front for the device and insertion, but spread across the 5-to-8-year life of the device they come out cheapest per year of all the methods.
Pills, patches, and rings need a prescription you can get via telehealth in under fifteen minutes in most states. The injection requires a clinic visit every three months. The IUD and implant require one insertion appointment — about 10 to 15 minutes for an implant, 5 to 10 for an IUD, with a day or two of cramping after. Insertion discomfort varies a lot; ask about local anesthetic options.
What changes
What changes in the first weeks is the period. Lighter, often dramatically — on the 52 mg hormonal IUD, many users stop bleeding entirely within a year. Less cramping, less PMS, fewer of the days you used to write off. For users with endometriosis, adenomyosis, or PCOS, the relief from cyclical pain or symptom burden often arrives within a few months. Acne typically clears on a combined pill in three to six months Arowojolu et al. 2012.
What changes over years is harder to feel and more important. Five years on a combined pill cuts ovarian cancer risk by about half, and the protection holds for three decades after you stop Collaborative Group 2008. The same window lowers endometrial and colorectal cancer risk. You'll never notice the cancer that didn't happen, but the actuarial picture is real.
What the conversation usually misses: knowing pregnancy is settled background math rather than a per-cycle worry changes the texture of the rest of the relationship. The person who isn't tracking late periods is a different person, in small ways, from the one who is.
Adjacent things worth knowing
If you had unprotected sex and need a backup right now: a copper IUD inserted within five days is the most effective option; levonorgestrel and ulipristal pills work up to 72-to-120 hours after, with effectiveness depending on which pill and when. Each is worth its own short read.
If you're planning pregnancy soon, the timing of stopping matters mostly for the injection (the 6-to-12-month return-to-ovulation lag); other methods can be stopped the cycle before trying. If you're after deeper coverage of period-related conditions in their own right — endometriosis, PMDD, PCOS — those are separate topics where hormonal contraception is one tool among several.
- — St John's wort can quietly lower the pill's hormone levels enough to cause a failure — check any supplement against your contraception.
- — St John's Wort speeds up how fast your body clears these hormones, which can quietly drop a pill's protection — a real cause of failure.
- — For adenomyosis, the levonorgestrel IUD is first-line treatment, not just contraception.
- — Used continuously to suppress ovulation, hormonal contraception is a core PMDD treatment, not just birth control.
- — Continuous hormonal contraception is a mainstay for controlling endometriosis pain.
- — Beyond birth control, the hormonal IUD and the pill are first-line treatments for heavy periods.
- — The combined pill is a workhorse for PCOS — it regulates cycles and calms the skin and hair symptoms.
- — For fibroid-driven heavy bleeding, the hormonal IUD is often the simplest effective option.
- — Still fertile in your 40s? A low-dose pill can steady the erratic perimenopausal bleeding and hot flashes while you still need contraception.
- — If you get migraine with aura, that changes which contraceptives are safe — combined estrogen pills raise stroke risk.
- — The same hormonal IUD that handles contraception can later serve as the progestin half of menopausal hormone therapy.
- — Going on or off a hormonal method reshapes your bleeding pattern — tracking it tells you what's normal for your method and what isn't.
Substance and claimed effects
Hormonal contraception is a family of methods that deliver synthetic estrogen and/or progestin to prevent pregnancy: combined oral contraceptive pills (COCs), progestin-only pills (POPs), the transdermal patch, the vaginal ring, depot medroxyprogesterone acetate (DMPA) injection, the etonogestrel subdermal implant, and levonorgestrel-releasing intrauterine systems (LNG-IUS). The primary claim is the suppression of ovulation and/or thickening of cervical mucus to prevent conception. Beyond contraception, the same hormones are prescribed (often off-label) for menorrhagia, dysmenorrhea, endometriosis-related pain, polycystic ovary syndrome (PCOS) symptom control, acne vulgaris, and premenstrual symptoms. This entry covers, holistically: contraceptive efficacy across methods, menstrual symptom modulation, mood and depression risk, libido, bone mineral density (particularly DMPA), the cancer-risk balance (ovarian/endometrial/colorectal protection vs. breast/cervical), and venous thromboembolism (VTE), arterial thrombosis, and stroke risk. Non-hormonal comparators — copper IUD, condoms, fertility-awareness methods, sterilization — are referenced for the choice architecture but are not the substance of the entry.
Evidence by addressing question
Mechanism
Combined estrogen-progestin methods (COC, patch, ring) suppress the hypothalamic-pituitary-ovarian axis: ethinylestradiol (or in newer pills, estradiol valerate / estetrol) provides negative feedback on FSH; the progestin component suppresses the LH surge, blocking ovulation. The progestin also thickens cervical mucus and thins the endometrium, providing secondary contraceptive barriers. Progestin-only methods (POP, DMPA, implant, LNG-IUS) vary in their primary mechanism: DMPA and the implant reliably suppress ovulation through sustained serum progestin levels; the LNG-IUS works primarily through local cervical-mucus thickening and endometrial atrophy, with ovulation suppressed in only a minority of cycles (especially with lower-dose devices like Kyleena/Skyla); traditional levonorgestrel-only POPs rely on cervical mucus and require strict 3-hour daily-dosing windows. Drospirenone-only POPs (Slynd) and the newer 24/4 dosing schedules sustain ovulation suppression with more forgiveness for missed doses CDC US-MEC 2016.
The menstrual effects follow from these mechanisms. Suppressed ovulation eliminates the cyclical progesterone fluctuation that drives PMS / PMDD symptoms; endometrial atrophy reduces menstrual blood loss substantially (mean reduction ~90% with the 52 mg LNG-IUS within 6 months) and reduces prostaglandin-driven dysmenorrhea. The anti-androgen effects of certain progestins (drospirenone, cyproterone acetate, norgestimate) plus the SHBG-elevating effect of ethinylestradiol lower free testosterone, the basis of acne and hirsutism improvement Arowojolu et al. 2012.
Evidence — efficacy
The decisive efficacy data come from the Contraceptive CHOICE Project (St. Louis cohort, n=7,486), which removed cost barriers and tracked typical-use failure rates over 3 years Winner et al. 2012. Unintended-pregnancy rates per 100 participant-years: implant 0.05, LNG-IUS 0.2, copper IUD 0.8, DMPA 0.1 (when on-schedule), pill/patch/ring 4.55, with a 20-fold higher failure rate for short-acting methods compared with LARC. Trussell's combined-method efficacy review confirms the typical-vs-perfect-use gap: COC perfect use 0.3% / typical use 9%; DMPA perfect 0.2% / typical 6%; condom perfect 2% / typical 18% Trussell 2011. The persistent gap between typical and perfect use is the central operational fact of contraception research: methods that don't depend on user adherence (implant, IUD) close it; methods that do (pill, patch, ring, DMPA) never do.
Evidence — VTE and arterial thrombosis
Combined hormonal contraceptives (CHCs) increase venous thromboembolism risk in a progestin-dependent way. The Danish national cohort (8.5M woman-years, 2001-2009) found absolute incidence of 6.29 per 10,000 woman-years on COCs vs 3.01 in non-users — relative risk ~3 over baseline Lidegaard et al. 2011. Second-generation levonorgestrel pills carried RR 2.9; third-generation desogestrel pills 6.6; drospirenone pills 6.3; cyproterone acetate 6.8. Vinogradova et al.'s 2015 BMJ nested case-control across two UK databases confirmed the rank-order with similar effect sizes (adjusted ORs of 2.4 for levonorgestrel up to 4.0 for drospirenone) Vinogradova et al. 2015. Absolute baseline VTE risk in a young healthy woman is ~2 per 10,000 woman-years; on a levonorgestrel pill ~6; on a drospirenone pill ~10 — still less than pregnancy (~29) and substantially less than postpartum (~300). Lidegaard's 2012 NEJM analysis of arterial events found CHC roughly doubled risk of ischemic stroke (RR 1.4-2.1 depending on dose) and MI (RR 1.3-2.3), absolute risk staying small in young low-risk women (~21 thrombotic strokes per 100,000 woman-years) but compounding sharply with smoking, age >35, hypertension, or migraine with aura Lidegaard et al. 2012. Progestin-only methods (POP, DMPA, implant, LNG-IUS) do not carry meaningful VTE risk; the LNG-IUS is the default recommendation in users with thrombotic history or CHC contraindications CDC US-MEC 2016 WHO MEC 2015.
Evidence — mood and depression
The Skovlund Danish cohort (n=1,061,997 women aged 15-34, followed 2000-2013) found a relative risk of 1.23 for first SSRI prescription within 6 months of starting any hormonal contraception, 1.34 for progestin-only methods, and 1.8 for adolescents aged 15-19 — translating to an extra ~2.2 antidepressant prescriptions per 100 person-years on COCs versus non-users Skovlund et al. 2016. The same group's 2018 follow-up linked current/recent hormonal contraception use to roughly doubled suicide attempt risk (RR 1.97) and tripled completed suicide risk (RR 3.08), with the strongest effect within the first two months of initiation Skovlund et al. 2018. These findings have not been uncontested: Worly et al.'s systematic review found inconsistent associations across 26 studies of progestin contraception and depression and concluded the evidence does not support a causal link in the general adult population, though the adolescent signal recurs Worly et al. 2018. The honest synthesis: a real, time-limited mood signal exists, concentrated in the first months after initiation and in adolescents, partially obscured at population level because the women most sensitive to hormonal mood changes self-discontinue and disappear from prevalence-based cross-sections (the healthy-user-on-treatment artefact). Conversely, for users with severe PMS/PMDD or endometriosis-associated mood symptoms, suppression of the cyclical progesterone surge can substantially improve mood — a within-group bidirectional effect that population averages obscure.
Evidence — libido
Pastor et al.'s systematic review across 36 studies (n>13,000) found that 85% of COC users reported unchanged libido, 21% improved, and 15% reported decreased sexual desire Pastor et al. 2013. The mechanism for the decrease is plausible: ethinylestradiol increases SHBG by 2-4 fold, reducing free testosterone, which correlates with desire in some women. The mechanism for the increase is also plausible: removal of pregnancy anxiety and improved partner-relationship dynamics. Selection bias is severe — women who lose libido often stop the method before being captured in cross-sectional studies, and switching method or formulation often resolves the effect. The clinical takeaway used in practice: if libido drops noticeably after starting, switching to a different progestin or to a non-CHC method is the first move.
Evidence — bone mineral density
DMPA is the major BMD concern. The FDA black-box warning (2004) was based on observational data showing 5-7% BMD loss at the spine and hip over 2 years of DMPA use, with reversal toward baseline after discontinuation. Kaunitz et al. 2008 reviewed the recovery data: in adult women, BMD recovers to baseline within 2-3 years of stopping; in adolescents, the timeline is longer but recovery is still observed Kaunitz et al. 2008. The clinical consensus from the Society for Adolescent Medicine and ACOG: DMPA's contraceptive benefit (and its high acceptability in some populations) outweighs the reversible BMD loss for most users; clinicians should not restrict duration of use solely because of BMD concerns, but should consider switching after several years or co-prescribing adequate calcium/vitamin D. COCs, the patch, the ring, the LNG-IUS, the implant, and POPs do not have a meaningful BMD signal.
Evidence — cancer risk balance
The headline tradeoff: combined oral contraceptives reduce ovarian, endometrial, and colorectal cancer risk substantially and durably; they slightly increase breast and cervical cancer risk during use, with risk returning to baseline within ~10 years of stopping. The pooled reanalysis of 45 epidemiological studies (n=23,257 ovarian cancers, 87,303 controls) found a 20% relative risk reduction per 5 years of COC use, with protection persisting 30+ years after stopping; the authors estimated this has averted ~200,000 ovarian cancers and 100,000 deaths globally to date Collaborative Group on Epidemiological Studies of Ovarian Cancer 2008. The 44-year follow-up of the RCGP Oral Contraception Study (n=46,022) confirmed: ever-users had lower lifetime risk of colorectal, endometrial, and ovarian cancers, no increase in overall cancer incidence, and lower all-cause mortality compared with never-users Iversen et al. 2017 Hannaford et al. 2010. Mørch et al.'s contemporary Danish cohort (n=1.8 million, n=11,517 breast cancers) found current/recent hormonal contraception use raised breast cancer RR to 1.20, with rising risk over longer-duration use; in absolute terms, one extra breast cancer case per ~7,690 women per year of use, with the excess concentrated in women >40 Mørch et al. 2017. The 24-study cervical cancer reanalysis found ~5-9 years of COC use roughly doubled cervical cancer risk during use among HPV-positive women, returning to baseline within 10 years of stopping; the mechanism is hormonal modulation of cervical HPV expression rather than HPV acquisition IARC 2007. Net mortality across long follow-up: the RCGP cohort found small overall reduction in all-cause mortality among ever-users vs never-users — the cancer-protection benefit and the small excess risks roughly cancel, with the balance leaning slightly positive at population scale Hannaford et al. 2010.
Practice / clinical guidelines
The CDC US Medical Eligibility Criteria for Contraceptive Use (US-MEC) and the WHO MEC are the operational guidelines used worldwide. They use a 4-category system: 1 (no restriction), 2 (advantages generally outweigh risks), 3 (risks generally outweigh advantages), 4 (unacceptable health risk) CDC US-MEC 2016 WHO MEC 2015. Absolute contraindications (category 4) for combined hormonal methods include: less than 21 days postpartum, current or history of DVT/PE not on anticoagulants, known thrombogenic mutations, current ischemic heart disease or stroke, migraine with aura, current breast cancer, severe cirrhosis, hepatocellular adenoma, uncontrolled hypertension (≥160/100), smoking ≥15 cigarettes/day and age ≥35, and complicated diabetes. Progestin-only methods are category 1 or 2 in nearly all of these scenarios, which is why the LNG-IUS is the default workaround for CHC-contraindicated patients. ACOG and the WHO endorse LARC (implant, IUDs) as first-line for most patients due to typical-use efficacy.
Misconceptions and community signal
Three pervasive misconceptions in lay discourse, each weakly supported or unsupported by the data: (1) "the pill makes you gain weight" — Cochrane reviews of COC and weight find no clinically significant effect; the only hormonal method with consistent weight gain is DMPA (mean 2-3 kg over the first year, more in some users); (2) "the pill ruins your fertility" — return to fertility post-discontinuation is rapid for all methods except DMPA, which can delay ovulation return by 6-12 months on average; (3) "you need to take breaks" — no medical basis, and breaks raise unintended-pregnancy risk. Community signal (reddit r/birthcontrol, large online cohorts) reflects strong volume on mood/libido side-effects, particularly with hormonal IUDs (despite the lower systemic exposure), and on the difficulty of distinguishing "the pill caused this" from baseline life stressors — a real epistemic problem the literature also grapples with.
The credibility range
Optimist case
Hormonal contraception is among the most consequential public-health innovations of the 20th century. LARC methods reach typical-use efficacy under 1% per year. The cancer ledger is net favorable: ovarian, endometrial, and colorectal cancer protection persists for decades after stopping; the breast cancer absolute excess is small and time-limited; all-cause mortality in long follow-up is slightly lower in ever-users Hannaford et al. 2010 Iversen et al. 2017. The non-contraceptive benefits — heavy menstrual bleeding control, dysmenorrhea, endometriosis pain, PCOS metabolic and dermatologic effects, PMS/PMDD relief, ovarian cyst suppression — substantially improve quality of life for many users, often in ways no other intervention matches. VTE absolute risk on modern low-dose COCs is small (~6 per 10,000 woman-years) and far below pregnancy-associated VTE risk (~29 per 10,000); the LNG-IUS and progestin-only methods avoid this risk entirely. The mood signal is concentrated in narrow time-windows and subgroups; for many users with cyclical mood disturbance, hormonal methods improve mood.
Skeptic case
The Danish Skovlund cohorts — among the largest, best-controlled studies of hormonal contraception ever conducted — found real, dose-response signals for depression (RR 1.23-1.8), antidepressant initiation, suicide attempts (RR 1.97), and completed suicide (RR 3.08), concentrated in adolescents and the first months of use Skovlund et al. 2016 Skovlund et al. 2018. The data on libido is poor — heavily confounded by selection bias against users who lose desire and discontinue — and likely underestimates a real effect. Modern third- and fourth-generation progestins double or triple VTE risk versus second-generation levonorgestrel formulations without offering meaningful clinical benefit; the marketing-driven preference for newer pills (drospirenone, cyproterone) has resulted in preventable thrombotic events Lidegaard et al. 2011 Vinogradova et al. 2015. The breast cancer excess, though small per user-year, is real and accumulates across millions of users globally. DMPA causes 5-7% BMD loss with unclear long-term fracture implications in adolescents. The medical system has historically minimized side-effects (mood, libido, weight) that women reported decades before formal studies confirmed them; the HRT-WHI history shows what happens when selection bias hides harms. Patients are not routinely offered fertility-awareness, copper-IUD, or vasectomy alternatives that lack hormonal exposure.
Author's call
Net population-level positive, but method choice matters enormously and the consent-process bar is higher than is typically delivered. For users prioritizing efficacy and tolerance: LNG-IUS or implant — typical-use failure under 0.2%, no VTE risk, no daily action, side-effect profile dominated by bleeding-pattern changes rather than systemic effects. For users wanting combined hormonal methods (e.g., for acne/PMS benefits): levonorgestrel-containing COC is the lowest-VTE-risk choice, with drospirenone/cyproterone reserved for specific dermatologic indications. For users with absolute CHC contraindications or who prefer no hormonal exposure: copper IUD matches LARC efficacy without hormones. The mood signal is real and the risk-window concentrated; clinicians should screen, and users should know that if mood deteriorates within the first months on any hormonal method, switching method class is the right response, not waiting it out. The breast cancer signal does not warrant blanket avoidance but does warrant honest disclosure. The DMPA bone signal is reversible but worth flagging for adolescents and users planning multi-year use. Controversy on the mood/libido magnitudes is genuine; the contraceptive efficacy and cancer-protection data are not contested.
Stakeholder and incentive map
- Pharmaceutical industry — substantial marketing investment behind newer-generation progestins (drospirenone-containing pills like Yaz, dienogest formulations), often framed as superior on tolerability without head-to-head efficacy or VTE data justifying preference over levonorgestrel COCs. Settlement history (Bayer/Yaz VTE settlements) suggests known harm signals were under-communicated.
- Professional bodies — ACOG, WHO, RCOG, NICE strongly endorse LARC-first prescribing, partly motivated by typical-use efficacy and partly by political imperatives around reducing unintended pregnancy. This is genuinely evidence-aligned but has compressed discussion of LARC-specific tradeoffs.
- Public health — Title X clinics, family-planning programs, and global development institutions push hormonal contraception for its population-scale fertility-reduction effects, sometimes at the expense of individualized side-effect counseling.
- Patient communities — online cohorts (r/birthcontrol, dedicated forums) are vocal about mood, libido, and bleeding-pattern side effects, often ahead of formal literature. The "natural" / fertility-awareness counter-culture is well-organized and sometimes overstates non-hormonal methods' typical-use efficacy.
- Counter-incentives — religious / pro-natalist movements politically oppose contraceptive access; this has historically intertwined with legitimate side-effect concerns and made disinterested risk communication politically difficult.
Population variability
- Adolescents (15-19) — strongest mood signal (RR for antidepressant start 1.8 vs 1.23 in adults); BMD accrual is incomplete, so DMPA is more conservatively prescribed; LARC adherence outcomes excellent; contraceptive efficacy especially valuable given high typical-use failure rates with short-acting methods Skovlund et al. 2016.
- Smokers age ≥35 — CHC contraindicated due to compounded MI/stroke risk; progestin-only methods preferred CDC US-MEC 2016.
- Migraine with aura — CHC contraindicated due to thrombotic stroke risk; progestin-only or copper IUD preferred.
- Postpartum and breastfeeding — CHC contraindicated first 21-42 days due to baseline elevated VTE; progestin-only methods, LNG-IUS, copper IUD all compatible with breastfeeding.
- Perimenopausal — non-contraceptive benefits (bleeding control, vasomotor symptoms) become central; LNG-IUS dual-purposes as endometrial protection during transitional HRT.
- PCOS — COC is first-line for menstrual regulation, hirsutism, acne; metabolic effects favorable.
- Endometriosis — continuous (no-pill-free-interval) COC, LNG-IUS, and dienogest formulations reduce pain; DMPA also effective.
- Personal or family history of VTE / thrombophilia — CHC contraindicated; LNG-IUS or copper IUD preferred.
- BRCA1/2 mutation carriers — ovarian cancer protection is high-magnitude and clinically important; breast cancer risk in already-elevated-risk carriers is debated but most data suggest small additive effect; case-by-case decision with oncology input.
Knowledge gaps
What hasn't been studied well: (1) long-term mood and cognitive trajectories from continuous adolescent-initiated hormonal contraception use over decades — most existing data captures 5-10 year windows; (2) the magnitude and reversibility of any persistent libido / SHBG-binding effects after long-term CHC discontinuation, with conflicting evidence from small studies; (3) head-to-head comparative data on side-effect profiles across modern formulations, since most trials are placebo-controlled or non-comparative; (4) hormonal contraception effects on the developing adolescent brain, where the hormonal milieu is itself a developmental signal; (5) whether the breast cancer signal is meaningfully different across LNG-IUS, COC, and implant — the existing Mørch data lumps them. What can't easily be studied: a true RCT of hormonal vs non-hormonal contraception over decades — selection bias and crossover make it intractable, so all population-scale data is observational. What would change the call: a well-powered RCT showing reproducible adolescent mood worsening that doesn't return to baseline would shift the recommendation toward delayed initiation or non-hormonal alternatives in this age band; a strong breast-cancer-recurrence signal in BRCA carriers would change BRCA prescribing.
Scope vs. brief. The brief named pregnancy prevention, menstrual symptoms, mood, libido, bone density, cancer risk, and VTE — all are covered. Bone density landed in the misconceptions section rather than getting its own block, because the DMPA-specific framing is most usefully delivered as "this fear is partial / mostly reverses" rather than as a standalone concern that overweights its real-world impact for the typical reader.
Mood score (1) was the hardest call. The Skovlund Danish cohort signal is real and big in adolescents (RR 1.8 for antidepressant initiation, RR ~2-3 for suicide attempts); Worly's systematic review reads the broader literature as not establishing causality. Net at population level is small and slightly negative on a benefit-dimension framework — but PMS/PMDD users get genuine relief, which is real positive on the same axis. Held the score at 1 to acknowledge real effect in both directions; the article carries the full nuance.
Action: decide vs. do. Treated as decide because the topic is fundamentally a choice among methods with clinician input, not a single behaviour to maintain. The reader's first action is picking; the daily action is method-specific and downstream.
Contraindications field uses just cardiac-condition and uncontrolled-hypertension. These apply to combined methods only, but they're the highest-stakes class-level flags. Progestin-only methods avoid most of them, which is what the article emphasises; over-tagging would have made the class look unsafe for users for whom the IUD/implant is in fact a first-line option.
Excluded from the article body: the BRCA1/2 prescribing question (case-by-case, oncology-coordinated — too specialised for this entry); detailed comparison of progestin generations beyond the levonorgestrel-vs-newer VTE rank-order; emergency contraception mechanism detail (signposted only); the cervical cancer-HPV interaction mechanism (signposted via citation).
Separate-entry candidates: emergency contraception; the copper IUD as a standalone entry (non-hormonal, distinct mechanism, distinct trade-offs); PMDD; endometriosis; PCOS; vasectomy. Each was raised by the writing and warrants its own entry rather than being collapsed in.
Future links to wire when published: emergency contraception, copper IUD, PMDD, endometriosis, PCOS, vasectomy, menopausal hormone therapy (the perimenopausal handoff in the audience section will want to link), and fertility-awareness methods.
Rating note on evidence (5): the contraceptive efficacy and ovarian-cancer protection data clear the 2+-rigorous-trials bar trivially. The mood and libido sub-literatures are individually weaker; the 5 reflects the overall research base, not uniformity of certainty across consequences.
Hormonal Contraception
Insurance usually covers everything. Generic pills are cheap; an implant or IUD costs more up front but lasts years.
Among the most studied medications ever — millions of women followed for decades. The big numbers are settled.
A pill every day, or one clinic visit every few years for an implant or IUD. Pick the rhythm that fits your life.
Periods get lighter, shorter, less painful — for many users that alone is the reason. Endometriosis pain, PMS, and PCOS symptoms ease too.
Combined pills clear acne for most users within a few months — the estrogen knocks down free testosterone, which is what drives the breakouts.
Five-plus years on the pill cuts ovarian cancer risk by about half, and the protection lasts for decades after you stop.
Most users feel no change. Some — especially teens and within the first few months — get noticeably more depressed; switching methods or stopping usually clears it.